IBM data seeing light of day

Richard Clapp, whose yet unpublished study of cancer deaths among IBM workers at semiconductor plants has been the subject of controversy, says he is finally submitting his data to a print journal.

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Richard Clapp, whose yet unpublished study of cancer deaths among IBM workers at semiconductor plants has been the subject of controversy, says he is finally submitting his data to a print journal. Clapp, who obtained the data from IBM as part of a court case brought against the company by former employees diagnosed with cancer, says he is "relieved to have finally gotten to this point." The paper found that semiconductor workers showed higher-than-average death rates from brain, skin, lymphatic, and hematopoietic tissue cancers.

The controversy began when Clinics in Occupational and Environmental Medicine refused to include the paper in the November 2004 issue dedicated to health issues related to the electronics industry (see http://www.the-scientist.com/news/20040623/04). In response, the guest editor, Joseph LaDou of the University of California School of Medicine, San Francisco, contacted all contributors and asked them to withdraw their articles until Clapp's paper is published. All agreed.

IBM ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies